GlycoMimetics’ Sickle Cell Candidate Nearly Ready For Hand-Over To Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech focused on role of carbohydrates in biological processes completes Phase II program of lead candidate for sickle cell disease. Under a 2011 partnership, Pfizer takes over development of GMI-1070 in Phase III.